Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 12:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pairing condition Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease

NCT02045056
View directory record Official record
Conditions
Preclinical Alzheimer's Disease
Interventions
Gemfibrozil, Placebo
Drug
Lead sponsor
Gregory Jicha, 323-5550
Other
Eligibility
65 Years to 90 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Sep 23, 2026, 12:59 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

NCT04603495
View directory record Official record
Conditions
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pelabresib, Ruxolitinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 23, 2026, 12:59 AM EDT
Completed Phase 4 Interventional

Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease

NCT00316992
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ramelteon and Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
40 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2010 · Synced Sep 23, 2026, 12:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mindful Parenting and Parent Training Program Study

NCT03796663
View directory record Official record
Conditions
Disruptive Behavior, Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder, Disruptive Behavior Disorder
Interventions
Mindful Parenting Program, MATCH BPT Program
Behavioral
Lead sponsor
New York University
Other
Eligibility
6 Years to 11 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 23, 2026, 12:59 AM EDT
Recruiting Not applicable Interventional

Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness (R33)

NCT06865937
View directory record Official record
Conditions
Schizophenia Disorder, Schizoaffective Disorder
Interventions
Mobile Intervention for Social Recovery in Serious Mental Illness (mSITE), Supportive Contact (SC)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 23, 2026, 12:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Online Expert Peer Facilitation of the EVERYbody Project

NCT05336253
View directory record Official record
Conditions
Body Image, Eating Disorder Symptom, Weight Bias
Interventions
EVERYbody Project-Connect, Self-Help Workbook
Behavioral
Lead sponsor
Western Washington University
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bellingham, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 23, 2026, 12:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Observational Study of Neuromuscular Function in CMT Type 1&2 and Healthy Controls

NCT04980807
View directory record Official record
Conditions
Charcot-Marie-Tooth Disease
Interventions
Not listed
Lead sponsor
NMD Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Sep 23, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission

NCT00382109
View directory record Official record
Conditions
B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Graft Versus Host Disease, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Interventions
thiotepa, cyclophosphamide, tacrolimus, methotrexate, sirolimus, total body irradiation
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
44
States / cities
Phoenix, Arizona • Duarte, California • Oakland, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Sep 23, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)

NCT02372799
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Placebo, Fluoxetine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 17 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
58
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 23, 2026, 12:59 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers

NCT07504601
View directory record Official record
Conditions
Healthy Volunteers
Interventions
(2R,6R)-Hydroxynorketamine, Placebo
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 60 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 23, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

NCT04536792
View directory record Official record
Conditions
Healthy Volunteers, Anemia, Sickle Cell
Interventions
AG-946, AG-946 Matched Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
8
States / cities
La Jolla, California • Boston, Massachusetts • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 23, 2026, 12:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)

NCT00908999
View directory record Official record
Conditions
Anosognosia, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
60 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 28, 2011 · Synced Sep 23, 2026, 12:59 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

NCT04493853
View directory record Official record
Conditions
Hormone-Sensitive Prostate Cancer
Interventions
Capivasertib, Placebo, Abiraterone Acetate
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Tucson, Arizona • La Jolla, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 23, 2026, 12:59 AM EDT
Completed Phase 4 Interventional

An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder

NCT02258828
View directory record Official record
Conditions
PTSD
Interventions
Memantine, Placebo
Drug
Lead sponsor
Sriram Ramaswamy
Federal
Eligibility
19 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Sep 23, 2026, 12:59 AM EDT
Terminated Phase 2 Interventional Results available

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

NCT03615144
View directory record Official record
Conditions
Non-Malignant Hematologic Disorders
Interventions
Melphalan, Thiotepa, Clofarabine, Fludarabine, Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®), CliniMACS reagents
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 69 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 23, 2026, 12:59 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

NCT04439175
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Taselisib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 23, 2026, 12:59 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Ultra High Field Magnetic Resonance Imaging as a Biomarker for Premotor Parkinson's Disease

NCT03288909
View directory record Official record
Conditions
Parkinson Disease, REM Sleep Behavior Disorder
Interventions
MRI
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced Sep 23, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

SPI-1005 for the Treatment of Meniere's Disease

NCT04677972
View directory record Official record
Conditions
Meniere Disease, Ménière
Interventions
Ebselen, Placebo
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Little Rock, Arkansas • Los Angeles, California • Roseville, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 23, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).

NCT03583372
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vibegron, placebos, Tolterodine Tartrate ER
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
107
States / cities
Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 23, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)

NCT05176639
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Veligrotug, Placebo
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
29
States / cities
Aurora, California • Beverly Hills, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 23, 2026, 12:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resources to Enhance the Adjustment of Children (REACH)

NCT00820001
View directory record Official record
Conditions
Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Booster Treatment, No-Booster, No intervention, Treatment As Usual
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Years to 11 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
2
States / cities
Cincinnati, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2013 · Synced Sep 23, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease

NCT04750577
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Placebo matching BI 685509, BI 685509
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Victorville, California • Waterbury, Connecticut • Hialeah, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 23, 2026, 12:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Multidimensional Study on Articulation Deficits in Parkinsons Disease

NCT05754086
View directory record Official record
Conditions
Parkinson Disease, Dysarthria, Hypokinetic
Interventions
Clear Speech, Less Clear Speech
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 23, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT02546700
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 80 Years
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Northridge, California • Palm Springs, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 23, 2026, 12:59 AM EDT